1. A renal transplant recipient is admitted three weeks post-transplant with a creatinine rise from 1.4 to 2.6 mg/dL over 48 hours. Tacrolimus trough is 19 ng/mL against a target of 8–12 ng/mL. The transplant team debates whether to treat empirically for rejection or obtain a biopsy first. Which of the following best explains why empirical treatment for rejection would be inappropriate in this clinical context, and what biopsy finding would confirm the correct diagnosis?

• A) Empirical rejection treatment is inappropriate because the patient's creatinine rise is too rapid for allograft rejection, which develops over weeks rather than days; biopsy would show interstitial fibrosis confirming chronic calcineurin inhibitor (CNI) nephrotoxicity rather than acute rejection.
• B) Empirical rejection treatment is inappropriate because supratherapeutic tacrolimus levels indicate the patient is over-immunosuppressed and cannot be rejecting; biopsy is unnecessary since rejection cannot occur with measurable drug above target trough.
• C) Empirical rejection treatment is inappropriate because the supratherapeutic tacrolimus trough strongly suggests acute calcineurin inhibitor (CNI) nephrotoxicity — characterized by afferent arteriolar vasoconstriction from excess thromboxane A2 and endothelin — rather than rejection; biopsy would show tubular vacuolization and afferent arteriolar hyalinosis without significant lymphocytic infiltration, distinguishing toxicity from the tubulitis and intimal arteritis of T-cell mediated rejection.
• D) Empirical rejection treatment is inappropriate because pulse corticosteroids are contraindicated within the first month post-transplant; biopsy would distinguish acute tubular necrosis from rejection by showing absence of peritubular capillary C4d deposition.
• E) Empirical rejection treatment is inappropriate because the clinical picture is consistent with calcineurin inhibitor (CNI)-mediated thrombotic microangiopathy; biopsy would show glomerular fibrin thrombi and schistocytes in glomerular capillaries, requiring plasmapheresis rather than augmented immunosuppression.

2. A renal transplant recipient on stable tacrolimus maintenance develops oral candidiasis and is started on fluconazole. Three days later she reports tremor and headache; her tacrolimus trough returns at 24 ng/mL (previous stable trough 7 ng/mL). Which mechanism explains this interaction, and what is the most appropriate immediate management step?

• A) Fluconazole potently inhibits cytochrome P450 3A4 (CYP3A4) — the principal enzyme responsible for tacrolimus hepatic and intestinal metabolism — causing rapid accumulation of tacrolimus to supratherapeutic and potentially toxic levels; immediate management requires tacrolimus dose reduction with close trough monitoring until levels return to the therapeutic range, and either substituting a non-azole antifungal or maintaining fluconazole at the lowest effective dose with continued dose adjustment.
• B) Fluconazole inhibits P-glycoprotein (P-gp) efflux transporter in the intestinal epithelium, preventing tacrolimus from being pumped back into the gut lumen and increasing net intestinal absorption; immediate management is to administer activated charcoal to bind unabsorbed tacrolimus and reduce ongoing absorption.
• C) Fluconazole displaces tacrolimus from plasma protein binding sites, increasing the free (unbound) tacrolimus fraction and pharmacodynamic effect without changing total tacrolimus plasma concentration; immediate management is reassurance that the total trough level remains therapeutic and no dose adjustment is needed.
• D) Fluconazole induces CYP3A4 at high doses used for systemic fungal infections, paradoxically increasing tacrolimus clearance and creating rejection risk; the supratherapeutic trough in this case reflects a laboratory error, and the trough should be rechecked before any dose adjustment.
• E) Fluconazole directly inhibits calcineurin in lymphocytes through a mechanism independent of tacrolimus, producing additive immunosuppression that lowers the effective immunosuppressive threshold of the tacrolimus dose; immediate management is to reduce both fluconazole and tacrolimus doses proportionally.

3. A renal transplant recipient on mycophenolate mofetil (MMF) reports persistent nausea, vomiting, and abdominal cramping that has required two dose reductions. The transplant pharmacist suggests switching to enteric-coated mycophenolate sodium (EC-MPS). Which of the following most accurately characterizes the expected benefit and limitation of this substitution?

• A) Switching to EC-MPS eliminates both upper and lower gastrointestinal adverse effects of mycophenolate because the enteric coating prevents mycophenolic acid (MPA) release throughout the gastrointestinal tract until the drug reaches the systemic circulation via lymphatic absorption, bypassing intestinal exposure entirely.
• B) Switching to EC-MPS is not appropriate because EC-MPS has a different active metabolite than MMF — EC-MPS releases mycophenolate sodium rather than mycophenolic acid (MPA) — producing a distinct immunosuppressive mechanism that requires separate dosing calibration and trough monitoring.
• C) Switching to EC-MPS substantially reduces the risk of MMF-associated bone marrow suppression because the enteric coating delays MPA peak concentration, reducing the maximum plasma level that bone marrow progenitors are exposed to and lowering the rate of leukopenia and thrombocytopenia.
• D) Switching to EC-MPS is contraindicated in renal transplant recipients because the delayed MPA release from the enteric coating reduces total drug bioavailability below therapeutic levels, increasing acute rejection risk without corresponding reduction in gastrointestinal adverse effects.
• E) Switching to EC-MPS may reduce upper gastrointestinal adverse effects (nausea, vomiting, epigastric pain) by delaying MPA release past the stomach and proximal duodenum; however, lower gastrointestinal adverse effects (diarrhea, cramping) are not reduced because much of the lower GI toxicity is mediated locally by MPA at the intestinal epithelium regardless of formulation.

4. A transplant surgeon notes that a protocol at a neighboring institution initiates sirolimus on post-operative day 3 to reduce calcineurin inhibitor (CNI) exposure from the outset. The surgeon expresses concern about this approach. Which of the following best identifies the specific complication that makes early post-operative sirolimus initiation hazardous, and the mechanism responsible?

• A) Early sirolimus initiation causes acute rejection in the first post-operative week because sirolimus blocks mTOR complex 1 (mTORC1) in regulatory T cells (Tregs), which require mTOR signaling for proliferation; depleting Tregs early removes the counter-regulatory brake on alloreactive T cells at the moment of highest alloantigen exposure.
• B) Early sirolimus initiation impairs surgical wound healing and vascular anastomotic repair because mTOR complex 1 (mTORC1) signaling is required for the proliferation and migration of fibroblasts and endothelial cells that carry out wound repair; perioperative mTOR inhibition increases the risk of anastomotic dehiscence, wound breakdown, and lymphocele formation around the transplanted kidney.
• C) Early sirolimus initiation causes acute CNI nephrotoxicity equivalent to supratherapeutic tacrolimus levels because sirolimus binds the same FKBP12 immunophilin as tacrolimus and competitively displaces tacrolimus from calcineurin, producing paradoxical calcineurin hyperactivation and excess afferent arteriolar vasodilation that floods the graft with immune cells.
• D) Early sirolimus initiation causes hyperacute rejection because mTOR inhibition prevents the upregulation of complement regulatory proteins on graft endothelium; without adequate CD55 and CD59 expression, complement is unregulated on graft vascular surfaces and donor-reactive antibodies cause immediate graft destruction.
• E) Early sirolimus initiation causes severe hyperlipidemia in the first post-operative week through mTORC1-mediated VLDL (very-low-density lipoprotein) overproduction in the liver, increasing thrombotic risk to newly anastomosed graft vessels and requiring immediate statin co-administration to prevent early graft thrombosis.

5. A 54-year-old man with a history of impaired fasting glucose receives a deceased-donor renal transplant. His endocrinologist is concerned about post-transplant diabetes mellitus (PTDM) risk. The transplant team is deciding between tacrolimus and cyclosporine as the calcineurin inhibitor (CNI) component of the maintenance regimen. Which statement best supports choosing cyclosporine over tacrolimus in this patient, and what is the mechanism underlying the difference in PTDM rates?

• A) Cyclosporine is preferred over tacrolimus in this patient because cyclosporine has a more favorable CYP3A4 interaction profile in patients with impaired glucose metabolism; diabetic patients have reduced CYP3A4 activity, causing tacrolimus to accumulate to nephrotoxic levels that secondarily impair renal glucose regulation.
• B) Cyclosporine is preferred over tacrolimus in this patient because cyclosporine does not require trough level monitoring in the early post-transplant period, reducing the frequency of phlebotomy and clinic visits that can disrupt glycemic management in patients with pre-existing glucose dysregulation.
• C) Tacrolimus is strongly preferred over cyclosporine in this patient because tacrolimus has a lower PTDM rate than cyclosporine; cyclosporine-mediated cyclophilin inhibition in pancreatic islet cells disrupts insulin gene transcription through a calcineurin-independent pathway that tacrolimus does not share.
• D) Cyclosporine is associated with substantially lower rates of PTDM than tacrolimus because tacrolimus more potently inhibits the calcineurin-NFAT signaling pathway in pancreatic beta cells — a pathway required for glucose-stimulated insulin secretion — making cyclosporine the preferred CNI in patients with pre-existing glucose dysregulation or elevated PTDM risk.
• E) Cyclosporine is preferred over tacrolimus in this patient because cyclosporine-mediated gingival hyperplasia and hirsutism provide indirect metabolic protection against PTDM through increased peripheral glucose utilization in proliferating gingival fibroblasts; tacrolimus lacks these metabolic side effects and therefore provides less glucose-buffering capacity.

6. A high-immunological-risk renal transplant recipient is receiving antithymocyte globulin (ATG) induction. During the first infusion, the patient develops fever, rigors, and hypotension. The infusion is stopped and the patient is stabilized. Which of the following correctly describes the appropriate premedication strategy for subsequent ATG doses, and the mechanism responsible for these infusion reactions?

• A) Premedication with tacrolimus dose escalation before each ATG infusion blunts the cytokine release syndrome by pre-saturating calcineurin and preventing T-cell-derived cytokine release during T-cell lysis; antihistamines and acetaminophen are not required because they do not address the calcineurin-mediated component of ATG infusion reactions.
• B) Premedication is not required for subsequent doses because first-dose reactions to ATG represent an IgE-mediated Type I hypersensitivity response to the murine protein component; desensitization occurs automatically after the first exposure, and subsequent infusions can be administered without premedication at a slower rate.
• C) Infusion reactions to ATG are caused by massive cytokine release as polyclonal antibodies lyse large numbers of T cells, activating complement and releasing tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and other pro-inflammatory mediators; subsequent doses require premedication with a corticosteroid (methylprednisolone), acetaminophen, and an antihistamine before each infusion to attenuate the cytokine release syndrome.
• D) Premedication with rituximab (anti-CD20 monoclonal antibody) before subsequent ATG doses depletes B cells that are amplifying the cytokine response through T-cell-dependent antibody production; acetaminophen is added for fever management but corticosteroids are contraindicated because they increase ATG T-cell depletion efficacy by blocking counter-regulatory T-cell responses.
• E) ATG infusion reactions are caused by complement activation by the polyclonal antibody Fc regions independent of T-cell lysis; premedication with eculizumab (a terminal complement inhibitor) before subsequent doses is the most targeted strategy, though acetaminophen and antihistamines are acceptable alternatives when complement inhibition is unavailable.

7. A renal transplant recipient who received high-dose methylprednisolone induction 18 months ago presents with progressive right hip pain that began insidiously four months ago and has worsened with weight-bearing. Plain radiograph of the hip is normal. Which corticosteroid-related complication should be highest on the differential, and what is the appropriate next diagnostic step?

• A) Avascular necrosis (osteonecrosis) of the femoral head is the most likely diagnosis — corticosteroids impair the vascular supply to bone through fat embolism, increased intraosseous pressure from fat cell hypertrophy, and direct osteocyte injury; it typically presents months to years after high-dose corticosteroid exposure with progressive joint pain, a normal early plain radiograph (X-ray misses early lesions), and characteristic signal changes on magnetic resonance imaging (MRI), which is the appropriate next diagnostic step.
• B) Corticosteroid-induced osteoporosis with femoral neck stress fracture is the most likely diagnosis — corticosteroids impair osteoblast function and increase osteoclast activity over months; although plain radiograph is normal, bone scintigraphy (nuclear bone scan) is more sensitive than MRI for early stress fracture detection and should be performed next.
• C) Corticosteroid-induced proximal myopathy affecting the hip girdle musculature is the most likely diagnosis — methylprednisolone causes type IIb muscle fiber atrophy through glucocorticoid receptor-mediated myosin heavy chain degradation; electromyography (EMG) is the appropriate next diagnostic step and will show a characteristic myopathic pattern without denervation potentials.
• D) Gout involving the hip joint is the most likely diagnosis in this transplant recipient — corticosteroid-mediated urate retention and the hyperuricemic effect of calcineurin inhibitors combine to produce exceptionally high serum urate; although hip gout is atypical, joint aspiration for crystal analysis is the appropriate next diagnostic step given the negative plain radiograph.
• E) Septic arthritis of the hip from an opportunistic pathogen is the most likely diagnosis in this immunosuppressed patient — corticosteroids impair leukocyte function and mask fever, allowing indolent fungal or mycobacterial hip infection to progress undetected; joint aspiration with culture for bacteria, fungi, and mycobacteria is the appropriate next diagnostic step.

8. A renal transplant recipient presents 14 months post-transplant with rising creatinine over three weeks. Donor-specific antibody (DSA) testing shows a strongly positive anti-HLA class II antibody at high mean fluorescence intensity. Allograft biopsy reveals peritubular capillary C4d deposition, peritubular capillaritis, and glomerulitis without significant tubulitis. Which treatment regimen correctly targets the pathophysiology of this rejection episode?

• A) Pulse methylprednisolone 500 mg intravenously daily for three consecutive days followed by antithymocyte globulin (ATG) at 1.5 mg/kg/day for 10–14 days if creatinine does not improve within five days; DSA positivity does not change the treatment algorithm because all acute allograft rejection shares the same T-cell-mediated effector mechanism.
• B) Sirolimus substitution for tacrolimus combined with mycophenolate mofetil (MMF) dose escalation; the mTOR inhibitor antiproliferative effect on B cells and plasma cells will reduce ongoing DSA production, and DSA levels will fall within two to four weeks without requiring plasmapheresis.
• C) Basiliximab re-induction at 20 mg intravenously on days 0 and 4 to block IL-2-driven expansion of alloreactive T cells; the C4d deposition and DSA positivity indicate that T-cell help to B cells is the primary pathological driver and IL-2 receptor blockade will interrupt both T-cell and B-cell activation simultaneously.
• D) Plasmapheresis to physically remove circulating donor-specific antibodies (DSAs), intravenous immunoglobulin (IVIG) administered after each plasmapheresis session to provide replacement immunoglobulins and modulate antibody effector function, and rituximab to deplete CD20-positive B cells and suppress de novo DSA production; this regimen targets the antibody-mediated mechanism distinguishing this episode from T-cell mediated rejection.
• E) Eculizumab — a terminal complement inhibitor (anti-C5 monoclonal antibody) — as monotherapy, given that C4d deposition confirms complement activation as the sole effector mechanism; plasmapheresis is unnecessary because complement inhibition neutralizes the downstream injury even if DSA levels remain elevated.

9. A renal transplant recipient is diagnosed with Banff grade IIA T-cell mediated rejection (TCMR) — significant tubulitis with mild intimal arteritis — and treated with pulse methylprednisolone 500 mg intravenously daily for three days. Six days after completing pulse steroids, the creatinine has not returned toward baseline and remains elevated. Which of the following correctly defines this clinical situation and describes the appropriate next step?

• A) This clinical situation represents adequate but delayed steroid response — creatinine improvement after pulse corticosteroids may take up to four weeks in grade IIA rejection with vascular involvement; the appropriate next step is to extend the observation period and repeat the biopsy at four weeks before considering additional treatment.
• B) This clinical situation meets the definition of steroid-resistant TCMR — failure of creatinine to return toward baseline within five to seven days of pulse corticosteroid therapy; the appropriate next step is antithymocyte globulin (ATG) at 1.5 mg/kg/day for 10–14 days to deplete the alloreactive T-cell population driving ongoing rejection.
• C) This clinical situation indicates treatment failure attributable to subtherapeutic calcineurin inhibitor (CNI) levels during the pulse steroid course; the appropriate next step is to check tacrolimus trough and optimize CNI exposure by empirically doubling the tacrolimus dose before considering salvage therapy with antithymocyte globulin.
• D) This clinical situation indicates antibody-mediated rejection (AMR) unmasked by steroid treatment; vascular involvement on biopsy (intimal arteritis) is the pathognomonic finding for AMR regardless of DSA status, and the appropriate next step is immediate plasmapheresis plus IVIG plus rituximab without awaiting DSA results.
• E) This clinical situation meets the definition of steroid-resistant TCMR; the appropriate next step is rituximab monotherapy at 375 mg/m² to deplete B cells that are providing T-cell help through antigen presentation and cytokine support, thereby indirectly reducing the alloreactive T-cell burden driving rejection.

10. A renal transplant recipient was converted from tacrolimus to sirolimus eight months ago for progressive CNI nephrotoxicity. She now presents with a three-week history of worsening dyspnea on exertion and dry cough. Chest computed tomography (CT) shows bilateral ground-glass opacities and mild interstitial thickening. Bronchoalveolar lavage (BAL) cultures are negative for bacteria, fungi, Pneumocystis jirovecii, and respiratory viruses. Which of the following is the most likely diagnosis and the most appropriate management?

• A) The most likely diagnosis is Pneumocystis jirovecii pneumonia (PCP) with a false-negative bronchoalveolar lavage due to inadequate sample volume; the appropriate management is empirical trimethoprim-sulfamethoxazole therapy at PCP treatment doses pending repeat bronchoscopy with a more proximal lavage site.
• B) The most likely diagnosis is sirolimus-exacerbated calcineurin inhibitor (CNI) nephrotoxicity causing volume overload and hydrostatic pulmonary edema; the appropriate management is to resume tacrolimus at a reduced dose and administer intravenous furosemide to reduce preload and resolve the bilateral pulmonary infiltrates.
• C) The most likely diagnosis is acute antibody-mediated rejection (AMR) of the allograft presenting with the pulmonary-renal syndrome; donor-specific antibody (DSA) production has damaged glomerular capillaries causing nephrotic-range proteinuria and pulmonary edema; the appropriate management is plasmapheresis plus IVIG plus rituximab.
• D) The most likely diagnosis is sirolimus-induced hyperlipidemia causing lipid pneumonitis from VLDL (very-low-density lipoprotein) deposition in the alveolar interstitium; the appropriate management is statin initiation at high intensity and sirolimus dose reduction to the lower end of the therapeutic range.
• E) The most likely diagnosis is sirolimus-associated non-infectious pneumonitis — a recognized class effect of mTOR inhibitors caused by mTORC1 inhibition in pulmonary interstitial cells — presenting with bilateral ground-glass opacities and negative infectious workup; the appropriate management is sirolimus discontinuation, with most cases resolving after the drug is stopped, and resumption of an alternative immunosuppressive regimen.

11. A renal transplant recipient with a stable tacrolimus trough of 6.8 ng/mL tests positive for latent tuberculosis on interferon-gamma release assay screening. The infectious disease team recommends a nine-month course of rifampin monotherapy. Which of the following correctly identifies the pharmacokinetic interaction that must be anticipated and the required clinical response?

• A) Rifampin competes with tacrolimus for FKBP12 binding in lymphocytes, reducing the effective pharmacodynamic concentration of tacrolimus even when plasma trough levels remain unchanged; the clinical response is to substitute cyclosporine for tacrolimus because cyclosporine binds cyclophilin rather than FKBP12 and is therefore not displaced by rifampin.
• B) Rifampin chelates tacrolimus in the gastrointestinal tract before absorption, reducing bioavailability; the clinical response is to switch tacrolimus from oral to intravenous administration for the duration of the rifampin course to bypass the chelation interaction.
• C) Rifampin inhibits CYP3A4 at high doses used for tuberculosis treatment, causing tacrolimus accumulation to supratherapeutic levels; the clinical response is to reduce the tacrolimus dose by 50% at rifampin initiation and recheck the trough after one week.
• D) Rifampin is a potent inducer of CYP3A4 and P-glycoprotein (P-gp), dramatically accelerating tacrolimus metabolism and intestinal efflux and causing a precipitous fall in tacrolimus trough to subtherapeutic levels within days of initiation; the clinical response is urgent tacrolimus trough monitoring beginning within three to five days of rifampin initiation, anticipating the need for major dose increases (often two- to five-fold) to maintain therapeutic immunosuppression and prevent acute rejection.
• E) Rifampin inhibits intestinal esterases responsible for tacrolimus activation, reducing the conversion of tacrolimus prodrug to its active metabolite; the clinical response is to substitute mycophenolate mofetil (MMF) for tacrolimus because MMF is not activated by the same esterase pathway and is unaffected by rifampin.

12. A transplant coordinator is educating a new fellow on basiliximab induction. The fellow asks why only two doses are given rather than a continuous infusion or weekly maintenance doses as used with other monoclonal antibodies in transplantation. Which of the following best explains the pharmacological rationale for basiliximab's two-dose induction schedule?

• A) Basiliximab requires only two doses because its target antigen — the IL-2 receptor alpha chain (CD25) — is rapidly downregulated from the T-cell surface after the first dose, rendering subsequent doses ineffective; the second dose on day four is given to capture any newly activated T cells that have not yet downregulated CD25.
• B) Basiliximab is given as only two doses because it carries a black-box warning for anaphylaxis that limits cumulative exposure; after two doses, the risk of a fatal anaphylactic reaction exceeds the immunosuppressive benefit, and continued IL-2 receptor blockade must be achieved by optimizing maintenance calcineurin inhibitor (CNI) levels.
• C) Basiliximab has an elimination half-life of approximately seven days; the two-dose schedule — one dose administered within two hours before transplantation and a second dose on post-operative day four — achieves sustained CD25 saturation throughout the critical early post-transplant window when alloreactive T-cell activation is highest, without requiring continuous infusion or additional doses.
• D) Basiliximab requires only two doses because the drug undergoes irreversible covalent binding to CD25 on the first dose, permanently blocking IL-2 receptor function on all T cells present at the time of transplantation; the second dose on day four targets newly produced T cells that have differentiated in the interval since the first dose.
• E) Basiliximab is given as only two doses because its chimeric structure produces neutralizing anti-drug antibodies (ADA) in virtually all patients by day seven; additional doses would be rapidly cleared by these neutralizing antibodies and provide no CD25 blockade; the second dose on day four is given before ADA development is expected to render further doses ineffective.

13. A 28-year-old woman who received a renal transplant two years ago is now in a stable relationship and wishes to discuss family planning with her transplant team. She is currently on tacrolimus, mycophenolate mofetil (MMF), and low-dose prednisone. Which of the following correctly describes the reproductive safety counseling she requires specifically regarding MMF, and what is the appropriate management if pregnancy is desired?

• A) MMF is teratogenic and causes a characteristic pattern of fetal malformations — including external ear abnormalities, cleft lip and palate, and cardiac defects — and carries an FDA Risk Evaluation and Mitigation Strategy (REMS) program requiring two reliable forms of contraception throughout treatment and for six weeks after discontinuation; if pregnancy is desired, MMF must be discontinued and substituted with azathioprine — which has a more favorable reproductive safety profile and is used for immunosuppression in pregnancy — at least six weeks before attempting conception.
• B) MMF is safe in pregnancy at doses below 720 mg twice daily because the FDA REMS program applies only to the higher-dose oncology regimen; the transplant team should optimize MMF to the lowest effective dose before conception is attempted, with monthly urine pregnancy testing throughout the first trimester.
• C) MMF teratogenicity is mediated through direct IMPDH inhibition in fetal lymphocytes and causes congenital combined immunodeficiency in neonates; it is safe to continue MMF through the first trimester because organ formation is complete before the lymphocyte depletion effect manifests, and the drug can then be discontinued for the second and third trimesters.
• D) The FDA REMS program for MMF requires paternal contraception as the primary protective measure because mycophenolic acid (MPA) concentrates in seminal fluid and causes paternally-mediated teratogenicity; maternal exposure to MMF at standard immunosuppressive doses does not carry teratogenic risk in published registry data.
• E) MMF is categorized as FDA Pregnancy Category B based on animal studies showing no teratogenic signal at therapeutic doses; the REMS program applies to males only because mycophenolic acid accumulates in testicular tissue and causes gonadal toxicity; females may continue MMF through pregnancy with standard prenatal monitoring.

14. A renal transplant recipient on azathioprine, tacrolimus, and prednisone develops severe pancytopenia — white blood cell count 1.1 × 10⁹/L, hemoglobin 7.4 g/dL, platelets 38 × 10⁹/L — at week three post-transplant. Azathioprine trough level is within the expected range. TPMT (thiopurine methyltransferase) genotyping returns homozygous loss-of-function variants. No allopurinol or other xanthine oxidase inhibitors are on the medication list. Which of the following correctly explains the mechanism of toxicity and identifies the appropriate long-term antiproliferative substitution?

• A) TPMT deficiency impairs conversion of azathioprine to its active thioguanine nucleotide metabolites, causing the parent compound to accumulate at toxic concentrations in hepatocytes; the appropriate substitution is sirolimus, which provides equivalent antiproliferative immunosuppression through mTORC1 inhibition without requiring TPMT-mediated activation.
• B) TPMT deficiency causes azathioprine to be shunted exclusively through the xanthine oxidase pathway to produce excess uric acid, causing hyperuricemia and urate nephropathy in the transplanted kidney; the appropriate substitution is mycophenolate mofetil (MMF), which does not produce uric acid as a metabolite.
• C) TPMT deficiency causes azathioprine to be preferentially converted to a hepatotoxic metabolite (methylmercaptopurine) through an alternative methylation pathway; the appropriate substitution is cyclosporine substituted for tacrolimus, combined with dose reduction, because tacrolimus shares the TPMT activation pathway and contributes to the pancytopenia.
• D) TPMT is the principal enzyme responsible for inactivating 6-mercaptopurine (the active azathioprine intermediate) through S-methylation; TPMT deficiency allows thioguanine nucleotides to accumulate to toxic levels in bone marrow progenitors, causing life-threatening myelosuppression even at standard doses; the appropriate long-term substitution is mycophenolate mofetil (MMF), which inhibits IMPDH in the de novo purine synthesis pathway and does not depend on TPMT for inactivation.
• E) TPMT deficiency causes azathioprine to bypass the purine synthesis pathway entirely and act as a direct DNA alkylating agent in bone marrow progenitors; the appropriate substitution is azathioprine dose reduction to 25% of the original dose, since partial TPMT activity at low doses is sufficient to prevent thioguanine nucleotide accumulation at reduced azathioprine exposure.

15. A renal transplant recipient who has been on tacrolimus-based triple immunosuppression for four years has a slow progressive rise in creatinine from 1.3 to 1.9 mg/dL over 18 months. Protocol biopsy shows moderate striped tubulointerstitial fibrosis with tubular atrophy, afferent arteriolar hyalinosis, and no significant lymphocytic infiltration. Tacrolimus troughs have been consistently therapeutic at 5–7 ng/mL throughout. Which of the following correctly identifies this diagnosis and the most appropriate pharmacological management strategy?

• A) The biopsy findings represent chronic antibody-mediated rejection (AMR) — striped tubulointerstitial fibrosis with arteriolar hyalinosis is the Banff histological signature of late AMR — and donor-specific antibody (DSA) testing should be performed; if DSA is positive, plasmapheresis plus IVIG plus rituximab should be initiated regardless of DSA titer.
• B) The biopsy findings represent chronic calcineurin inhibitor (CNI) nephrotoxicity — the characteristic striped tubulointerstitial fibrosis driven by long-term TGF-β stimulation — a process that is largely irreversible; the appropriate management is CNI minimization, specifically conversion from tacrolimus to an mTOR inhibitor-based regimen (sirolimus or everolimus) to reduce ongoing TGF-β-mediated fibrogenesis and slow progressive graft dysfunction.
• C) The biopsy findings represent recurrent IgA nephropathy in the allograft — the predominant pattern of post-transplant recurrent glomerular disease — presenting with mesangial fibrosis after four years; the appropriate management is intensification of triple immunosuppression with higher tacrolimus targets and fish oil supplementation.
• D) The biopsy findings represent acute CNI nephrotoxicity from cumulative dose effect at the four-year mark; since tacrolimus levels are therapeutic and not supratherapeutic, the arteriolar hyalinosis is caused by long-standing systemic hypertension rather than tacrolimus, and the appropriate management is intensification of antihypertensive therapy without changing the immunosuppressive regimen.
• E) The biopsy findings represent T-cell mediated rejection (TCMR) at the chronic stage — chronic active TCMR is characterized by tubulointerstitial fibrosis and tubular atrophy with intermittent lymphocytic infiltration that may be absent on any single biopsy; the appropriate management is pulse corticosteroid therapy followed by long-term prednisone dose increase.

16. A 47-year-old woman is presenting for her second renal transplant. Her first graft failed from chronic rejection five years ago. Panel reactive antibody (PRA) is 74%, and pre-transplant crossmatch identifies donor-specific antibodies (DSAs) against the incoming donor's HLA-DQ antigens. The transplant team is selecting an induction agent. Which of the following best justifies the selection of antithymocyte globulin (ATG) over basiliximab in this patient, and what is the specific clinical consideration that makes ATG the more appropriate choice?

• A) ATG is preferred over basiliximab in this patient because basiliximab is contraindicated in patients with pre-formed donor-specific antibodies (DSAs); DSAs compete with basiliximab for CD25 binding on activated T cells, reducing basiliximab efficacy to zero in sensitized recipients and making T-cell depletion the only viable induction strategy.
• B) ATG is preferred over basiliximab because this patient's high PRA indicates she has antibodies against the donor's T cells specifically; ATG, which contains antibodies directed against the same T-cell surface antigens targeted by the patient's own panel reactive antibodies, will synergize with these pre-formed antibodies to achieve more rapid T-cell depletion than ATG alone.
• C) ATG is preferred over basiliximab in this patient because the second transplant operation carries higher surgical complexity and longer cold ischemia time, producing more ischemia-reperfusion injury; ATG's T-cell depletion prevents the inflammatory cytokine burst from ischemia-reperfusion injury from activating alloreactive T cells, an effect that basiliximab's non-depleting mechanism cannot achieve.
• D) ATG is preferred over basiliximab because this patient has a 74% PRA, indicating she has circulating antibodies against 74% of all potential donor antigens; basiliximab, which targets the IL-2 receptor, cannot neutralize these pre-formed antibodies and requires plasmapheresis to be co-administered with every dose, making ATG the more practical single-agent induction strategy.
• E) ATG is preferred over basiliximab because this patient is high immunological risk — defined by her prior sensitization, PRA of 74%, repeat transplant history, and detected donor-specific antibodies — requiring the deeper initial T-cell depletion that ATG provides; basiliximab's non-depleting IL-2 receptor blockade provides insufficient immunosuppression for the large alloreactive T-cell burden present in highly sensitized recipients, placing the graft at substantially higher acute rejection risk.